Get the Stockscreener App
8.25
15.38%
-1.50
After Hours:
8.28
0.03
+0.36%
Trevi Therapeutics Inc stock is traded at $8.25, with a volume of 3.62M.
It is down -15.38% in the last 24 hours and up +12.55% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$9.75
Open:
$9.7
24h Volume:
3.62M
Relative Volume:
1.78
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-28.45
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
+17.69%
1M Performance:
+12.55%
6M Performance:
+30.95%
1Y Performance:
+150.00%
1-Day Range:
$8.012
$9.70
1-Week Range:
$6.98
$9.92
52-Week Range:
$2.36
$9.92
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
8.25 | 1.17B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Initiated | Morgan Stanley | Overweight |
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Polar Asset Management Partners Inc. Purchases New Shares in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Raymond James Financial Inc. Has $3.20 Million Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighShould You Buy? - MarketBeat
Cubist Systematic Strategies LLC Grows Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics, Inc. $TRVI Stock Position Raised by Acorn Capital Advisors LLC - MarketBeat
Exome Asset Management LLC Acquires New Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Octagon Capital Advisors LP Takes Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $21.75 - MarketBeat
Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley - uk.finance.yahoo.com
Trevi Therapeutics (NASDAQ:TRVI) Trading 8.9% HigherHere's Why - MarketBeat
Trevi Therapeutics stock hits 52-week high at $8.80 - Investing.com
Trevi Therapeutics stock hits 52-week high at $8.80 By Investing.com - Investing.com South Africa
Adage Capital Partners GP L.L.C. Sells 2,060,000 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics at Morgan Stanley Conference: Strategic Focus on Cough Treatments - Investing.com Canada
Is Trevi Therapeutics Inc. stock poised for growthWeekly Investment Report & Growth Oriented Trading Recommendations - Newser
15 Best Multibagger Stocks to Invest in Right Now - Insider Monkey
Retail Trends: Is Trevi Therapeutics Inc. stock technically oversoldBull Run & Consistent Return Investment Signals - Lancaster City Council
What the charts say about Trevi Therapeutics Inc. today2025 Retail Activity & Technical Buy Zone Confirmations - Newser
What Fibonacci levels say about Trevi Therapeutics Inc. rebound2025 Institutional Moves & Free Weekly Chart Analysis and Trade Guides - Newser
Tools to assess Trevi Therapeutics Inc.’s risk profile2025 Volatility Report & Weekly Top Gainers Trade List - Newser
Trevi Therapeutics Inc. stock daily chart insightsPortfolio Growth Summary & Daily Growth Stock Tips - Newser
Visualizing Trevi Therapeutics Inc. stock with heatmapsMarket Activity Summary & Fast Moving Market Watchlists - Newser
Heatmap analysis for Trevi Therapeutics Inc. and competitors2025 Valuation Update & Weekly High Return Opportunities - Newser
Panagora Asset Management Inc. Purchases 219,600 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Market reaction to Trevi Therapeutics Inc.’s recent newsJuly 2025 Pullbacks & Short-Term Swing Trade Alerts - Newser
Is Trevi Therapeutics Inc. stock ready for a breakoutMarket Movement Recap & Accurate Entry and Exit Point Alerts - Newser
Multi asset correlation models including Trevi Therapeutics Inc.Weekly Profit Recap & High Win Rate Trade Tips - Newser
Trevi Therapeutics Inc. stock trendline breakdownMarket Performance Summary & Weekly High Potential Alerts - Newser
Ally Bridge Group NY LLC Cuts Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Frazier Life Sciences Management L.P. Lowers Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
MPM Bioimpact LLC Grows Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Charles Schwab Investment Management Inc. Purchases 34,455 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Using AI based signals to follow Trevi Therapeutics Inc.Buy Signal & Weekly Stock Performance Updates - Newser
What is the target price for Trevi Therapeutics Inc. stockWeekly Stock Analysis & Accurate Intraday Trade Tips - خودرو بانک
Why Trevi Therapeutics Inc. is moving today2025 Top Decliners & Daily Profit Focused Stock Screening - Newser
Pattern recognition hints at Trevi Therapeutics Inc. upsideBuy Signal & Safe Capital Investment Plans - Newser
Armistice Capital LLC Acquires New Shares in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Has Trevi Therapeutics Inc. found a price floorJuly 2025 Selloffs & Expert-Curated Trade Recommendations - Newser
What data driven models say about Trevi Therapeutics Inc.’s futureMarket Rally & Safe Entry Trade Reports - Newser
How does Trevi Therapeutics Inc. score in quality rankingsForecast Cut & Free Reliable Trade Execution Plans - خودرو بانک
Is Trevi Therapeutics Inc. forming a bottoming baseQuarterly Trade Review & Real-Time Market Sentiment Reports - Newser
Volume spikes in Trevi Therapeutics Inc. stock – what they meanMarket Growth Review & Consistent Profit Trading Strategies - Newser
Will Trevi Therapeutics Inc. stock go up soonJuly 2025 PostEarnings & Weekly High Return Opportunities - Newser
Tools to monitor Trevi Therapeutics Inc. recovery probabilityEntry Point & Free Technical Confirmation Trade Alerts - Newser
Trevi Therapeutics, Inc. $TRVI Shares Acquired by Jump Financial LLC - MarketBeat
Will Trevi Therapeutics Inc. outperform the market in YEARJuly 2025 Movers & Verified Momentum Stock Ideas - خودرو بانک
Can Trevi Therapeutics Inc. hit a new high this monthWeekly Market Report & Advanced Swing Trade Entry Plans - Newser
Can Trevi Therapeutics Inc. reach resistance levels soonJuly 2025 Highlights & Weekly High Return Forecasts - خودرو بانک
Trevi Therapeutics Inc.’s volatility index tracking explainedQuarterly Profit Review & Short-Term High Return Ideas - Newser
Statistical indicators supporting Trevi Therapeutics Inc.’s strengthTrade Entry Report & AI Enhanced Market Trend Forecasts - Newser
Can Trevi Therapeutics Inc. keep up with sector leadersJuly 2025 Fed Impact & Weekly Top Performers Watchlists - خودرو بانک
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):